Early phase I study of a 99m Tc labeled anti-PD-L1 sdAb in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer
Y Xing, G Chand, C Liu, L Zhao, HH Ting, J Zhao - 2019 - Soc Nuclear Med
83 Purpose: Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-
1)/programmed death ligand (PD-L1) antibodies demonstrates improvements in treatment of …
1)/programmed death ligand (PD-L1) antibodies demonstrates improvements in treatment of …
Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung …
Y Xing, G Chand, C Liu, GJR Cook… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Purpose: Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-
1)/programmed death ligand (PD-L1) antibodies demonstrates improvements in treatment of …
1)/programmed death ligand (PD-L1) antibodies demonstrates improvements in treatment of …
Early phase I study of a 99mTc-labeled anti–programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non–small …
Y Xing, G Chand, C Liu, GJR Cook… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-1)/programmed
death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced …
death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced …
SPECT/CT using [99mTc]-labeled anti-programmed death-ligand 1 (PD-L1) single-domain antibody (NM-01) to predict response to immune checkpoint inhibition in …
D Hughes, G Chand, L Meszaros, K Adamson… - 2022 - Soc Nuclear Med
2594 Introduction: Immune checkpoint inhibition with anti-programmed cell death protein 1
(PD-1) or programmed death-ligand 1 (PD-L1), alone or in combination with chemotherapy …
(PD-1) or programmed death-ligand 1 (PD-L1), alone or in combination with chemotherapy …
[PDF][PDF] Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell …
DJ Hughes, G Chand, V Goh… - EJNMMI …, 2020 - ejnmmires.springeropen.com
Purpose: Checkpoint inhibition therapy using monoclonal antibodies against programmed
cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small …
cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small …
[HTML][HTML] Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT …
DJ Hughes, G Chand, J Johnson, D Bailey… - EJNMMI research, 2023 - Springer
Background Immune checkpoint inhibitors, including those against programmed cell death
protein-1 (PD-1) or its ligand (PD-L1), are routinely used to treat non-small cell lung cancer …
protein-1 (PD-1) or its ligand (PD-L1), are routinely used to treat non-small cell lung cancer …
Assessing PD-L1 expression in non-small cell lung cancer patients using68Ga-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody PET/CT
239 Introduction: The recent rise of checkpoint inhibitor therapy, predominantly programmed
cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies as a standard care of …
cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies as a standard care of …
[HTML][HTML] RETRACTED ARTICLE: Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) …
Purpose Checkpoint inhibition therapy using monoclonal antibodies against programmed
cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small …
cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small …
Comparison of PD-L1 mRNA expression measured with the CheckPoint Typer® assay with PD-L1 protein expression assessed with immunohistochemistry in non …
R Erber, R Stoehr, S Herlein, C Giedl… - Anticancer …, 2017 - ar.iiarjournals.org
Background: Immunohistochemical (IHC) assessment of programmed death-ligand 1 (PD-
L1) in non-small cell lung cancer (NSCLC) has become important since the development of …
L1) in non-small cell lung cancer (NSCLC) has become important since the development of …
[HTML][HTML] Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer
A Popple, TM Illidge - Translational Cancer Research, 2017 - tcr.amegroups.org
Targeting the programmed death 1/programmed cell death ligand-1 (PD-1/PD-L1) immune
checkpoint pathway in non-small cell lung cancer (NSCLC) with anti-PD-1 and anti-PD-L1 …
checkpoint pathway in non-small cell lung cancer (NSCLC) with anti-PD-1 and anti-PD-L1 …